Translational meeting
7-8 June 2022, Stockholm, Sweden
Translational science – from bench to bedside ↓
Limb ischaemia – from pathophysiology to clinic
This meeting aims to merge basic researchers, physicians and industry to give scientific updates on burning issues.
Oral abstract presentations and posters with Young Investigator Awards
in collaboration with
and 
REGISTRATION
Click on your category on the right
Accommodation
ESVS has blocked rooms in the closest hotel to the venu: Carolina Elite Hotel
Venue
Bioclinicum
Auditorium Sune Bergstrom
Solnavägen 30
171 64 Solna
Sweden
Sponsors
If you are a medical company, join us onsite as an exhibitor!
Social Event
The City Hall of Stockholm and the Region of Stockholm invite all participants for a networking evening.
If you are interested, please book your free ticket: the names of all participants need to be communicated to the City Hall in advance
Transport
Taxi, bus, train… You have many options to reach the venue.
TAXI: 31mn / 45€
FLYGBUSSARNA BUS: 31mn / 12€ (stop at Karolinska Sjukhuset Eugeniavägen)
TRAIN+BUS: 50mn / (Arlanda Express + 3 > stop at Karolinska Sjukhuset Eugeniavägen)
Accreditation
The ESVS Translational Meeting, taking place from 7th to 8th June, 2022 in Stockholm, Sweden has been granted 10 European CME credits (ECMEC®s) by the European Accreditation Council for
Continuing Medical Education (EACCME®).
PROGRAMME
| Tuesday, 7th June 2022 |
||
| 12:00-12:05 | Welcome address | |
| Session 1: CLTI – the deadly CVD partner |
||
| 12:05 | Clinical introduction – the Unmet needs : Health impact of CLTI | Birgitta Sigvant, Sweden |
| 12:20 | Keynote lecture: Thearpeutic advances in CVD treatment | Nick Leeper, USA |
| 12:50 | Genetics of muscle inflammation in chronic limb-threatening ischemia: The TNF-α hypothesis | Diego Caicedo Valdés, Spain |
| 13:05 | Vein Bypass versus Nitinol Stent in Long Femoropopliteal Lesions. 4-Year Results of a Randomized Controlled Trial | Florian Enzmann, Austria |
| 13:20 | Proprotein Convertase Subtilisin/Kexin Type 6 (PCSK6) plays a Role in Angiogenesis Regulation | Melody Chemaly, Sweden |
| 13:35 | Arterial vs. venous cytokine profile in patients with LEAD | Riikka Tulamo, Finland |
| 13.50 | Gender related differences in chronic limb threatening ischemia due to femoro-popliteal disease | Laura Yáñez García, Spain |
| 14.05 | Panel Discussion | |
| 14:15-15:15 | Coffee break & poster viewing | |
| Session 2: From bad to worse – ALI in the pandemic |
||
| 15:15 | Clinical introduction – the Unmet needs: COVID-19 and ALI IRL | Christian-Alexander Behrendt, Germany |
| 15:30 | Keynote lecture:COVID-19 and vascular dysfunction | Christer Betzholtz, Sweden |
| 16:00 | COVID-19 infection and acute mesenteric ischemia | Tina Cohnert, Austria |
| 16:30 | The influence of gut microbiome metabolites on endothelial junction integrity – implications for aortic dissection? | Thorsten Eierhoff, Germany |
| 16:45 | Panel discussion | |
| 17:00 – 18:00 | Poster viewing | |
| 19:00 | City hall banquet | |
,
| Wednesday, 8th June 2022 |
||
| Session 3: Mitigating failure after CLTI treatment |
||
| 08:00 | Clinical introduction – the Unmet needs : Clinical aspects on CLTI reconstrcution failure | Joe Mills,USA |
| 08:15 | Keynote lecture: The pathophysiology of lower limb atherosclerosis | Aloke Finn, USA |
| 08:45 | Determining the mechanism and safety of vessel preparation devices in calcified tibial arteries with histologic validation | Trisha Roy, USA |
| 09:00 | Cystathionine gamma lyase (CGL) enzyme activity is crucial in hindlimb ischemia recovery through NAD-dependent mechanisms | Kevin Kiesworo, Switzerland |
| 09:15 | Sodium Thiosulfate, a source of Hydrogen Sulfide, promotes angiogenesis and revascularization via metabolic reprogramming of endothelial cells. | Florent Allagnat, Switzerland |
| 09:30 | Panel Discussion | |
| 10:00-11:00 | Coffee break & poster viewing | |
| Session 4: The worst of the worst-Diabetic CLTI |
||
| 11:00 | Clinical introduction – the Unmet needs: The clinical manifestations of diabetic CLTI | Florian Dick, Switzerland |
| 11:15 | Keynote lecture:The pathophysiology behind diabetic vasculopathy and CLTI | Kathryn Gallagher, USA |
| 11:45 | Calcification and inflammation related pathways are induced in atherosclerotic plaques of diabetic patients | Glykeria Karadimou, Sweden |
| 12:00 | Evaluation of microcirculatory changes before and after endovascular intervention using a new multimodal imaging system | Sofie Aronsson, Sweden |
| 12:15 | Evaluation of the angiosome concept using near-infrared fluorescence with indocyanine green. | Bien Ferrari, Netherlands |
| 12:30 | Microcirculation assessment of the foot using laser speckle contrast imaging during endovascular and hybrid revascularisation procedures in patients with chronic limb threatening ischemia | Bryan Wermelink, Netherlands |
| 12:45 | Near-infrared fluorescence with indocyanine green to predict clinical outcome after revascularization. | Floris Tange, Netherlands |
| 13:00 | Panel discussion | |
| 13:15-14:15 | Lunch & poster viewing | |
| Session 5:Emerging horizons in CLTI management | ||
| 14:15 | Clinical introduction – the Unmet needs:Recent clinical developments | Joakim Nordanstig, Sweden |
| 14.30 | Keynote lecture:CLTI R&D | Nabil Chakfé, France |
| 15.00 | Fibrin-based bioartificial blood vessels – The journey towards a biologically active vascular prosthesis for peripheral revascularization | Florian Helms, Germany |
| 15.15 | Vascular grafts collagen coating resorption and healing process in humans | Salomé Kuntz, France |
| 15:30 | Creation of functional autologous arteriovenous fistulae in a large animal model using a synthetic biodegradable graft | Paul J. Besseling, Netherlands |
| 15:45 | Leukocyte- and platelet rich fibrin (L-PRF) as a treatment of refractory vascular ulcers: first results of a prospective cohort study. | Dries Dorpmans, Belgium |
| 16:00 | Panel discussion & prize ceremony | |
| 16:15 | Adjourn | |
